Studies

Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review.

Annals of internal medicine|2026|Batsis J et al.

BACKGROUND: Incretin-based therapies induce substantial weight loss and are widely prescribed; disproportionate losses in fat-free mass (FFM) and skeletal muscle are a concern. PURPOSE: To evaluate body composition changes associated with incretin th…

ReviewSemaglutide

GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling.

Science progress|2026|Gupta A et al.

ObjectiveTo evaluate glucagon-like peptide-1 receptor agonist (GLP-1 RA)-specific associations with hair loss, characterize reported alopecia subtypes and discuss potential underlying mechanisms.MethodsA systematic literature search was conducted acr…

ReviewSemaglutide Tirzepatide

PMID: 41998799

GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.

Annals of medicine|2026|Chikatimalla R et al.

OBJECTIVES: To evaluate the current evidence supporting the cerebrovascular protective effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in individuals with type 2 diabetes mellitus (T2DM), and to outline their mechanisms of action in s…

ReviewSemaglutide

PMID: 41999297

Glucagon-like peptide-1 receptor agonists (GLP1RA) in the management of mitochondrial diabetes in an adolescent: A Case Report.

Hormone research in paediatrics|2026|Hayes E et al.

INTRODUCTION: Mitochondrial diabetes is rare and typically treated with dietary intervention and oral hypoglycaemic agents. Most require insulin. Novel treatments are available but are not well-characterised. PRESENTATION: A 16-year-old adolescent gi…

Case ReportSemaglutide

PMID: 41999618

Impact of GLP-1 RA plus progestin therapy on fertility-sparing management of endometrial intraepithelial neoplasia and endometrial cancer.

Gynecologic oncology|2026|Hsieh T et al.

OBJECTIVE: We examined whether the addition of GLP-1RA to progestin therapy reduced the risk of hysterectomy in patients with endometrial intraepithelial neoplasia (EIN) and endometrial cancer (EC) in the U.S. managed with fertility-sparing managemen…

Semaglutide Tirzepatide

PMID: 42000371

Glycyl-L-histidyl-L-lysine-Cu2(GHK-Cu) Attenuates CuSOor LPS induced-inflammation in Zebrafish larvae model.

European journal of pharmacology|2026|Hu J, Zhang C, Wang F

Inflammation serves as a basic defense mechanism against both internal and external threats, while the unresolved or excessive inflammation can lead to irreversible tissue damage. Glycyl-L-histidyl-L-lysine-Cu(GHK-Cu), a bioactive tripeptide complex…

GHK-Cu

PMID: 41997403

GIPR:GCGR co-agonism restores normal weight in obese rodents.

Molecular metabolism|2026|Perez-Tilve D et al.

OBJECTIVE: Functional co- and tri-agonists at the receptors for GLP-1, GIP and glucagon effectively decrease body weight and hyperglycemia but are associated with adverse gastrointestinal effects related to GLP-1R agonism. Here we report the discover…

Animal StudyRetatrutide

PMID: 41997446

Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants.

Journal of hematology & oncology|2026|Lin P et al.

ABSTRACT: Dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium–glucose cotransporter 2 (SGLT2) inhibitors are widely prescribed for their cardiometabolic benefits, yet their hematologic oncologic sa…

Tirzepatide

PMID: 41957612

Tirzepatide as an Add-on for Participants with Inadequate Glycemic Control Using Basal Insulin: Pooled Subgroup Analysis of SURPASS-5 and -6.

Diabetes therapy : research, treatment and education of diabetes and related disorders|2026|Bajaj H et al.

INTRODUCTION: This study aimed to assess the efficacy and hypoglycemia safety of tirzepatide as an add-on to basal insulin in people with inadequate glycemic control, across subgroups of baseline age, type 2 diabetes (T2D) duration, HbA1c, and basal…

Tirzepatide

PMID: 41961454

Real-world weight impact upon tirzepatide discontinuation at a single-center endocrinology clinic in patients with overweight or obesity.

Journal of the American Pharmacists Association : JAPhA|2026|Huang L et al.

BACKGROUND: Overweight and obesity are major contributors to cardiovascular-kidney-metabolic (CKM) disease. Tirzepatide (TZP-MJ), originally approved for type 2 diabetes (T2D), has demonstrated significant weight loss beyond glycemic improvement. Des…

Tirzepatide

PMID: 41962807

Tirzepatide in Metabolically Dysfunctional-Associated Steatohepatitis (MASH): A Bibliometric and Evidence-Based Review.

Journal of diabetes research|2026|Pantea I, Repanovici A

PURPOSE: Metabolically-dysfunction-associated steatohepatitis (MASH) is the progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD) and is strongly linked to obesity and type 2 diabetes mellitus (T2D). Tirzepatide, a dual…

ReviewTirzepatide

PMID: 41964153

Health-Related Quality of Life and Work-Related Outcomes in People with Obesity or Overweight Treated with Tirzepatide or Other Obesity Medications: United States Results from the Adelphi Real World Obesity Disease Specific Programme™.

Advances in therapy|2026|Gibble T et al.

INTRODUCTION: This real-world exploratory study in the United States (US) aimed to describe the socio-demographics, clinical characteristics, health-related quality of life (HRQoL), and work-related outcomes among people with obesity (PwO) undergoing…

Tirzepatide

PMID: 41965443

Ketoacidosis associated with tirzepatide use in a nonobese individual without diabetes.

JCEM case reports|2026|Kemmotsu R et al.

Euglycemic ketoacidosis is metabolic acidosis with elevated ketone bodies despite normal or mildly elevated glucose levels and has rarely been reported in nonobese individuals without diabetes using tirzepatide. A 23-year-old Japanese woman without o…

Case ReportTirzepatide

PMID: 41971636

Correction: Semaglutide Mitigates Ischemic Brain Injury by Inhibiting Ferroptosis via Modulation of FoXO1 and DRP1 Pathways.

Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review.

GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling.

GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.

Glucagon-like peptide-1 receptor agonists (GLP1RA) in the management of mitochondrial diabetes in an adolescent: A Case Report.

Impact of GLP-1 RA plus progestin therapy on fertility-sparing management of endometrial intraepithelial neoplasia and endometrial cancer.

Impact of semaglutide pretreatment on reproductive outcomes in women with overweight and obesity with infertility: a real-world multicenter cohort study.

Glycyl-L-histidyl-L-lysine-Cu2(GHK-Cu) Attenuates CuSOor LPS induced-inflammation in Zebrafish larvae model.

GIPR:GCGR co-agonism restores normal weight in obese rodents.

Tolerability and Effectiveness of Tirzepatide in Kidney Transplant Recipients: Real-world Experience From a Single-center Study.

Targeting the activin/myostatin - actrii pathway to preserve skeletal muscle mass in obesity: mechanistic insights and therapeutic perspectives.

Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants.

Tirzepatide as an Add-on for Participants with Inadequate Glycemic Control Using Basal Insulin: Pooled Subgroup Analysis of SURPASS-5 and -6.

PCSK9 Inhibitors in Diabetes, Tirzepatide's Cardiorenal Effects, Shingles Vaccine, and More From ACC.

Real-world weight impact upon tirzepatide discontinuation at a single-center endocrinology clinic in patients with overweight or obesity.

Tirzepatide in Metabolically Dysfunctional-Associated Steatohepatitis (MASH): A Bibliometric and Evidence-Based Review.

Health-Related Quality of Life and Work-Related Outcomes in People with Obesity or Overweight Treated with Tirzepatide or Other Obesity Medications: United States Results from the Adelphi Real World Obesity Disease Specific Programme™.

Real-world prescribing patterns and early weight and blood pressure outcomes of GLP-1-based therapies: a retrospective observational study in the United Arab Emirates.

Ketoacidosis associated with tirzepatide use in a nonobese individual without diabetes.

Commentary on: "Ixekizumab with Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity".